carfilzomib

Carfilzomib (PR-171) is a proteasome inhibitor that irreversibly binds to the chymotrypsin of the 20S proteasome. Carfilzomib has antitumor activity and may be used to treat multiple myeloma.

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

Carfilzomib-D8 (Standard) is a reference standard of Carfilzomib-D8 intended for quantitative analysis, quality control, and related biochemical research applications. Carfilzomib-d8 is the deuterated form of Carfilzomib. Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.

Carfilzomib Impurity 2 is a pharmaceutical intermediate used in the synthesis of various active compounds.

Carfilzomib-D8 is the deuterated form of Carfilzomib. Carfilzomib (T1795) (PR-171) is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells.

CFLZ-567 is a key intermediate for making carfilzomib.

WRR139 is a peptide vinyl sulfone derivative that acts as a potent inhibitor of cytosolic N-glycanase 1 (NGLY1) and the transcription factor Nrf1. NGLY1-mediated deglycosylation is essential for the maturation and activation of Nrf1. By inhibiting NGLY1, WRR139 impairs Nrf1 processing, localization, and activation, thereby suppressing the compensatory expression of proteasome genes. WRR139 significantly potentiates the cytotoxicity of Carfilzomib against cancer cells, serving as a valuable tool for studying proteostasis and overcoming resistance to proteasome inhibitors.

HRS 4642 is a long-acting, selective KRAS G12D inhibitor with a Kd value of 0.083 nM. It inhibits phosphorylation of downstream MEK and ERK proteins, exhibiting antitumour activity. HRS 4642 reduces target lesions and, when used alone or in combination with Carfilzomib, remodels the tumour microenvironment towards an immunocompetent state.

NC-002 is a cell-penetrating peptide and functions as an inhibitor of the trypsin-like proteasome (Trypsin-likeproteasome), without affecting the activity of lysosomal cysteine proteases. It is an epoxyketone derivative of Leupeptin. NC-002 enhances the sensitivity of myeloma cells to Bortezomib and Carfilzomib and is utilized in cancer research.